Amgen Expects Quick, Broad Adoption Of Tezspire In Severe Asthma

Company says new asthma drug partnered with AstraZeneca will offer a new therapy option for severe patients with low eosinophil counts. The firms will provide launch plans in January.

Neon Light Sign Lungs Icon
Tezspire offers a new therapeutic option for severe asthma patients with low eosinophil counts

More from New Products

More from Scrip